I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors at 8:00 a.m. EST on December 14 to provide an in-depth analysis of the most recent clinical data from an ongoing clinical trial of lemzoparlimab in combination with rituximab in relapsed or refractory non-Hodgkins’s lymphoma. I-Mab Conference Call Information Investors and analysts are invited to join the conference call at 8:00 a.m. EST on December 14 via Zoom: Meeting URL: https://zoom.us/j/91421936788?pwd=Z0VUK1dDYmdQZWRYTVgxcVZ3eDdIQT09 Meeting ID: 914 2193 6788Password: 2(…) Read More »

Exit mobile version